When non-small cell lung cancer patients with EGFR gene mutation are facing the dilemma of drug resistance, a “third-generation targeted drug” called ositinib mesylate is quietly rewriting the treatment landscape.
Today, we will bring you an in-depth exploration of the scientific code behind this innovative drug, which is known as the “lung cancer nemesis”.
You may have heard of it under the trade name “Teresa”, an oral targeted drug developed by AstraZeneca and specifically designed to overcome the EGFR T790M resistance mutation. As the benchmark of third-generation EGFR-TKI, it not only accurately combats cancer cells, but also has the “super power” of penetrating the blood-brain barrier, allowing patients with brain metastases to regain their lives.
The savior of drug-resistant patients: when the first/second generation of targeted drugs fail, T790M mutation exists in 79% of cases, which is exactly the main target of ocitinib.
A new standard of care for first-line treatment: New research shows that initial treatment can extend median progression-free survival to a staggering 18.9 months
Brain metastasis: its unique molecular structure makes its concentration in cerebrospinal fluid (CSF) 15 times higher than that in blood, rewriting the survival outcome of patients with brain metastasis.
Second, unveiling the anti-cancer black science and technology: how it is precisely guided?
Imagine how this “smart missile” works:
Precise identification: locking the C797 site of EGFR kinase structural domain through acrylamide group.
Permanent Sequestration: Forms covalent bonds to irreversibly inhibit the activity of the T790M mutant.
Intelligent barrier avoidance: only 1/10th of the effect on wild-type EGFR of the first-generation drugs, dramatically reducing side effects such as skin rashes
Double mutation strike: simultaneous inhibition of sensitive mutations (e.g. exon 19 deletion) and drug-resistant mutations
Metabolic upgrade: active metabolite AZ5104 maintains long-lasting efficacy.
Brain penetration: special lipophilic design breaks through the blood-brain barrier.
The ultimate pursuit of production process
In the clean room of a GMP factory in Tianming, engineers are tackling key processes:
Crystallization control: the crystalline purity of methane sulfonate has a direct impact on bioavailability and requires precise control of temperature and humidity profiles.
Chiral purification: the ee value of the key intermediate (R)-3-amino-4-(2-cyanobenzyl)cyclohexane must be >99.9%.
Impurity profile control: 15 potential genotoxic impurities are monitored by UPLC-QTOF.
We have been deeply plowing into the field of targeted pharmaceutical raw materials for 15 years, providing:
✅ Whole industry chain service: seamless transition from gram-scale clinical samples to ton-scale commercial production.
✅ Dynamic Quality System: Establishment of PAT process analysis technology under QbD concept.
✅ Global Compliance Support: DMF filing has been completed in China, USA and Europe, accelerating customers’ formulation filing.
Act now to seize the first opportunity in R&D!
Whatever you need:
➤ Custom synthesis services
➤ Reference formulation reverse analysis
➤ Consistency evaluation technical support
24-hour professional docking channel has been opened
📧 Email: sunqian0123@gamil.com
📱 WhatsApp: +86 176 6371 3557
This guide compares T/T, L/C, D/P and D/A for pharmaceutical intermediate purchases, with worked costs on a $60,000 order and the seven mistakes buyers make.
An impurity absent from a Certificate of Analysis is not necessarily absent from the process — it may simply have been purged downstream. This guide explains impurity fate mapping, purge factors, ICH M7 Option 4, and the five documents buyers should request.
This checklist shows buyers how to qualify a second supplier in six steps — documentation, batch consistency, quality agreements, and activation triggers included.
Manufacturer and supplier of pharmaceutical APIs and intermediates. Contact us for technical support and sourcing solutions.